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Gouty arthritis results from the generation of monosodium urate (MSU) crystals within
joints. These MSU crystals elicit acute inflammation characterized by massive infiltration
of neutrophils and monocytes that are mobilized by the pro-inflammatory cytokine IL-1β.
MSU crystals also activate the complement system, which regulates the inflammatory
response; however, it is unclear whether or how MSU-mediated complement activation
is linked to IL-1β release in vivo, and the various roles that might be played by individual
components of the complement cascade. Here we show that exposure to MSU crystals
in vivo triggers the complement cascade, leading to the generation of the biologically
active complement proteins C3a and C5a. C5a, but not C3a, potentiated IL-1β and
IL-1α release from LPS–primed MSU-exposed peritoneal macrophages and human
monocytic cells in vitro; while in vivo MSU–induced C5a mediated murine neutrophil
recruitment as well as IL-1β production at the site of inflammation. These effects
were significantly ameliorated by treatment of mice with a C5a receptor antagonist.
Mechanistic studies revealed that C5a most likely increased NLRP3 inflammasome
activation via production of reactive oxygen species (ROS), and not through increased
transcription of inflammasome components. Therefore we conclude that C5a generated
upon MSU-induced complement activation increases neutrophil recruitment in vivo
by promoting IL-1 production via the generation of ROS, which activate the NLRP3
inflammasome. Identification of the C5a receptor as a key determinant of IL-1-mediated
recruitment of inflammatory cells provides a novel potential target for therapeutic
intervention to mitigate gouty arthritis.
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INTRODUCTION
Gout is the most common form of inflammatory arthritis
and is associated with a substantial public health burden
(Rees et al., 2014). The clinical prognosis for gout remains
unsatisfactory, considering the intense pain of acute flares, loss
of productivity, impairment of physical function, and long-term
complications, including morbidities and mortality (Rees et al.,
2014). Novel therapeutic strategies for gout are therefore needed,
especially for patients who are refractory to or intolerant of
conventional treatment (e.g., non-steroidal anti-inflammatory
drugs, colchicine, or glucocorticoids). Emerging data have shown
that aberrant expression of complex signaling pathways are
involved in the inflammation of gout (Santegoets et al., 2011; Jin
et al., 2014). Understanding the specific mechanisms driving the
production of key cytokines involved in these pathways may offer
improved prospects for the development of more efficacious and
less toxic therapies (Dinarello and van der Meer, 2013; Goh et al.,
2014; Perez-Ruiz et al., 2014).
Gout is caused by deposition of monosodium urate (MSU)
crystals into the joints, which provokes a massive infiltration of
inflammatory cells, mainly neutrophils and monocytes (Dalbeth
et al., 2016). The interaction of these immune cells with
the MSU crystals heightens inflammation, leading to further
recruitment of increasing numbers of immune cells into the
joint and escalation of the condition. IL-1 plays a pivotal role
in gout-associated inflammation by instigating the release of
multiple pro-inflammatory cytokines and chemokines (IL-8, IL-
6, CXCL8, CXCL1), and the upregulation of adhesion molecules
(selectins, integrins) on endothelial cells, which directly induces
a massive infiltration of inflammatory cells (i.e., neutrophils and
monocytes) at the site of crystal deposition (Brown et al., 1994;
Hachicha et al., 1995). Prolonged accumulation of these cells can
result in irreversible destruction of joint tissues and increases
the risk of chronic inflammation. Therapies directed toward
mitigating MSU-induced neutrophil infiltration and activation
may therefore be beneficial for gout patients.
The exact mechanisms driving the release of IL-1β had
remained elusive until the discovery that MSU crystals activate
the NLRP3 inflammasome in myeloid cells of the immune
system (Martinon et al., 2006; Giamarellos-Bourboulis et al.,
2009; Kingsbury et al., 2011). NLRP3 belongs to the family
of intracellular NOD-like receptors that, upon sensing of
pathogen- or danger-associated molecular patterns (PAMPs and
DAMPs, respectively), recruits the adaptor protein ASC, which
aggregates and forms the inflammasome complex (Zambetti
et al., 2012; Broderick et al., 2015). ASC molecules, in turn,
recruit the precursor of caspase-1 (pro-casp-1), which undergoes
autoproteolysis and is then able to process pro-IL-1β and pro-IL-
18 to their active forms (Zambetti et al., 2012; Broderick et al.,
2015).
In vitro, MSU crystals alone, much like other particulates
(e.g., calcium pyrophosphate dihydrate crystals, silica, aluminum
hydroxide), are not able to activate the NLRP3 inflammasome
autonomously unless a “priming” pattern recognition signal,
such as TLR ligands or proinflammatory cytokines, is provided
alongside (Bauernfeind et al., 2009; Franchi et al., 2009): this
priming signal is required for the transcription of pro-IL-1β
and NLRP3 genes, whose products are activated by the second
stimulus. However, in vivo, inflammatory responses are elicited
by MSU crystals in the sterile environment of the joint space,
implying that myeloid cells in this context have already received
a priming signal, the source of which is currently unknown.
One of the mechanisms through which MSU crystals can
induce inflammation is through activation of the complement
system (Giclas et al., 1979). The complement cascade can
be activated by the classical, lectin, and alternative pathways,
with all pathways converging at the formation of the C3
and C5 convertases, which are required for the generation of
the biologically active complement peptides (also known as
anaphylatoxins), C3a and C5a, as well as the formation of
the membrane attack complex (MAC) on target cells (Merle
et al., 2015a). MSU crystals can activate both the classical and
alternative pathways of the complement system (Doherty et al.,
1983). In particular, formation of an active C5 convertase on the
crystal surface was shown to trigger the cleavage of C5 proteins
into C5a and C5b subunits (Russell et al., 1982). C5a is a potent
chemoattractant factor for neutrophils and monocytes (Ricklin
et al., 2010), and can also elicit the production of inflammatory
cytokines, including IL-1β, as well as chemokines released by both
endothelial cells and phagocytes (i.e., macrophages and dendritic
cells; Laudes et al., 2002; Monsinjon et al., 2003).
Activated complement components have been detected in
synovial fluids from gout patients during acute attacks (Doherty
et al., 1988; Brodeur et al., 1991). Moreover, the MAC has been
shown to promote neutrophil recruitment in a rabbit model of
experimental gout arthritis (Tramontini et al., 2004). However,
the chemoattractant properties of C5a and C3a have yet to be
well-investigated in the context of gouty inflammation: indeed,
it remains unclear whether or how these anaphylatoxins might
instigate neutrophil and monocyte recruitment during crystal
deposition, or contribute to IL-1β release in vivo.
In this study, we show that MSU crystals activate the
complement system in myeloid cells, leading to generation of
C3a and C5a. C5a, but not C3a, regulates IL-1β release in vitro
and in vivo, and is thereby responsible for the recruitment
of neutrophils and monocytes to the site of MSU-induced
inflammation. Blockade of C5a receptor signaling markedly
decreased leukocyte infiltration, and suggests that therapeutic
targeting of C5a may prove beneficial in treating acute and
chronic gouty arthritis.
MATERIALS AND METHODS
Mice
C57BL/6 (B6) and Balb/c mice were purchased from the
Biological Resource Center ((BRC), Agency for Science,
Technology, and Research (A∗STAR), Singapore). C3−/− (stock
# 003641; on B6 background), C5ar1−/− (stock #006845) and
C3ar1−/− mice (stock # 005712; both on Balb/c background)
were from The Jackson Laboratory. Double C3ar1−/− and
C5ar1−/− mice were generated by crossing C5ar1−/− and
C3ar1−/− mice. All experiments were conducted with gender-
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and age-matched mice, and all mutants were backcrossed to
B6 or Balb/c backgrounds for at least 10 generations. Animals
were bred under specific pathogen-free conditions at the BRC
(A∗STAR, Singapore) and experiments were performed under
the approval of the Institutional Animal Care and Use Committee
(IACUC) in compliance with the Law and Guidelines for Animal
Experiments of the BRC (A∗STAR, Singapore).
In vitro Stimulation of Peritoneal
Macrophages
Mice received an intraperitoneal (i.p.) injection of Brewer
thioglycollate medium (3%) to increase macrophage yield and
euthanized 3 days later. Peritoneal macrophages were collected
by lavage of the peritoneal cavity with 10 ml fresh RPMI medium.
Red blood cell lysis was performed using hypotonic ammonium
chloride solution (0.084%) for 5 min at room temperature.
Peritoneal macrophages were plated at 2 × 105/well in 96-well
plates, and stimulated with E. coli LPS (0.1 µg/ml) for 3 h with or
without MSU (250µg/ml) for an additional 4 h, in the presence of
recombinant C3a (0.25 and 1.25 µg/ml) or C5a (1–10–50 ng/ml).
After 24 h, cell culture supernatants were collected.
Human monocytic (THP1) cells were plated at 1 × 105/well
in 96-well plates and treated with PMA (200 nM) overnight
to differentiate monocytes into macrophages. Cells were then
washed and exposed to E. coli LPS (0.1 µg/ml) for 3 h with or
without MSU (250 µg/ml) for an additional 4 h, in the presence
of recombinant C5a (1–10–50 ng/ml). After 24 h, cell culture
supernatants were collected.
Monosodium Urate (MSU)-Mediated
Peritonitis
Eight- to ten-week-old wild-type (WT), C3−/−, C3ar−/−,
C5a−/−, and C3ar−/− C5ar−/− mice were injected i.p. with
3 mg MSU crystals in 0.5 ml of saline. Control mice were
injected with saline alone. After 6 h, mice were euthanized with
CO2 and peritoneal exudate cells were collected by lavage with
cold medium. The resulting cell suspensions were centrifuged
before red blood cell lysis using hypotonic ammonium chloride
solution for 5 min at room temperature, then quantification
of cell number. In some experiments, mice received linear C5a
receptor antagonistic peptide (1 mg/kg of mouse weight, AnaSpec
Inc) by i.p. injection 5 min prior to MSU treatment.
Flow Cytometry
Total peritoneal cells were labeled with CD11b-APC (M1/70,
eBioscience), Ly6C-PE-Cy7 (HK1.4, Biolegend), and Ly6G-PE
(1A8, BD PharMingen) for 15 min at room temperature. Cells
were then washed with PBS twice before analysis using a
Fortessa flow cytometer (BD Biosciences). Data were analyzed
using FlowJo (Treestar). Neutrophils were identified as CD11b+
Ly6G+ cells and monocytes as CD11b+ Ly6C+ Ly6G− cells.
ELISA
IL-1α and IL-1β were measured using DuoSet ELISA kits (R&D
Systems), following the manufacturer’s instructions. C3a and C5a
levels in peritoneal lavage fluids were quantified by a sandwich
ELISA as previously described (Kandasamy et al., 2013). The
following antibody pairs were used: rat anti-mouse C3a or C5a
capture antibody (2 µg/ml, overnight, 4◦C), and biotinylated rat-
anti mouse C3a or C5a detection antibody (2 µg/ml, 1 h, room
temperature), all from BD Pharmingen. The absorbance was read
at 450 nm with the reference wavelength at 570 nm, using a Tecan
M200 Infinite plate reader (Tecan).
Quantitative RT-PCR
Quantitative RT-PCR was performed using the
following validated SYBR Green primers: Nlrp3, 5′-CCT
CTAGCTTCTGCCGTGGTCTCT-3′ and 5′-CGAAGCAGCAT
TGATGGGACA-3′; Asc, 5′-CTGAGCAGCTGCAAACGACTA
AA-3′ and 5′-CTTCTGTGACCCTGGCAATGAGT-3′; Casp1,
5′-CTGTCAGGGGCTCACTTTTCATTG-3′ and 5′-AATGTCC
CGGGAAGAGGTAGAAAC-3′; Il1a, 5′-TCAGCACCACTTGG
TAAATGAC-3′ and 5′-GTGTTTCTGGCAACTCCTTCAGC-3′;
Il1b, 5′-GGTCAAAGGTTTGGAAGCAG-3′ and 5′-TGTGAAA
TGCCACCTTTTGA-3′; Gapdh, 5′-TCGTCCCGTAGACAAAA
TGG-3′ and 5′-TTGAGGTCAATGAAGGGGTC-3′. Amplifi-
cation was performed using an Applied Biosystems 7500 Real-
Time PCR System. The relative expression level of each gene was
evaluated using the 11Ct method. The difference between the
Ct of the target gene and the Ct of the Gapdh housekeeping gene
was normalized to the1Ct of the untreated condition.
ROS Production
Intracellular production of reactive oxygen species (ROS) was
quantified using the H2DCFDA fluorometric method: briefly,
peritoneal macrophages were labeled with H2DCF-DA (20 µM;
BioChemika Fluka) for 30 min and then washed with PBS before
2 × 105 cells per well were seeded into black 96-well plates.
Cells were incubated with C5a (50 ng/ml) or without, for 5 h
before fluorescence was measured at 10-min intervals for 100 min
using the Infinite M200 plate reader (Tecan; excitation 485 nm,
emission 538 nm). ROS levels are displayed as the percentage
increase in ROS relative to untreated controls.
Statistical Analysis
Statistical significance was assessed using unpaired two-tailed t
tests. Data were analyzed using Prism 7 (GraphPad).
RESULTS
C5a, But Not C3a, Boosts IL-1α/β
Release from Peritoneal Macrophages
We first examined the interaction of the complement
components C3a and C5a with macrophages in vitro. Mouse
peritoneal macrophages were primed with LPS, and incubated
with MSU crystals or not in the presence or absence of increasing
concentrations of recombinant C3a or C5a. In the absence of
MSU crystals, LPS alone, LPS and C3a, LPS and C5a did not
induce the release of IL-1β and IL-1α (Figures 1A,B); while the
addition of MSU crystals triggered the release of both IL-1α
and IL-1β from macrophages (Figures 1A,B). This mechanism
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FIGURE 1 | C5a enhances IL-1α and IL-1β release from peritoneal macrophages and a human monocytic cell line. LPS-primed mouse peritoneal
macrophages (A,B) were incubated or not with C3a alone (0.25 and 1.25 µg/ml; A), C5a alone (1–10–50 ng/ml; B), or with C3a or C5a in combination with MSU
crystals (250 µg/ml). (C) LPS-primed human THP1 monocytic cells were left untreated or treated with C5a alone (1–10–50 ng/ml) or in the presence of MSU crystals
(250 µg/ml). Culture supernatants were collected after 24 h and IL-1α/β levels were measured by ELISA. Values are shown as means ± standard error; n = 3.
∗∗p < 0.01; ∗p < 0.05. nd, none detected.
is consistent with the established dual activation model of
the NLRP3 inflammasome, in that LPS is required to drive
expression of the IL-1β precursor and NLRP3, while a second
signal, such as MSU crystals, controls inflammasome formation
and activation of caspase-1.
Macrophages co-stimulated with LPS/MSU crystals and
increasing concentrations of C5a boosted IL-1β and IL-1α
production in a dose-dependent manner (Figure 1B), whereas
C3a had no such effect (Figure 1A). Similar results were
obtained when the human monocytic THP1 cell line was used
(Figure 1C). These data indicate that IL-1α/β release from
peritoneal macrophages and human monocytic cells requires
both LPS and MSU crystals, and that C5a, but not C3a, boosts
this inflammasome-mediated release.
MSU-Induced Complement Activation
Elicits Neutrophil and Monocyte
Recruitment in a Mouse Model of Gout
The mechanisms underlying complement-mediated recruitment
of inflammatory leukocytes by MSU crystals in vivo are largely
unknown. Therefore we first evaluated the ability of MSU
crystals to activate the complement cascade in vivo by measuring
amounts of C3a and C5a in the peritoneal fluid of mice following
injection of MSU crystals, or vehicle only, into the peritoneal
cavity of two commonly used mouse strains, C57Bl/6 and Balb/c.
Two hours after MSU crystal injection C3a and C5a levels
significantly increased in the lavage fluids from both C57Bl/6
(Figure 2A) and Balb/c mice (Figure 2B), relative to control
animals, confirming that MSU crystals have the capacity to
activate the complement cascade in vivo.
To evaluate the importance of the complement cascade
in sterile inflammation induced by MSU crystals in vivo, we
next assessed the infiltration of neutrophils and inflammatory
monocytes into the peritoneal cavity of C3−/− mice, which
are unable to activate the complement cascade beyond the
formation of the C3-convertase. C3−/− and wild-type (WT)
control mice were injected i.p. with MSU crystals or vehicle;
after 6 h, cells were collected by peritoneal lavage, labeled
for surface molecule expression and characterized by flow
cytometry. WT animals receiving MSU crystals exhibited a robust
inflammatory response, characterized by massive peritoneal
infiltration of neutrophils and monocytes, compared to mice
receiving vehicle (Figures 3A,B). MSU-elicited mobilization
of neutrophils and monocytes in the peritoneal cavity of
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FIGURE 2 | Monosodium urate (MSU) crystals induce rapid activation of complement in vivo. C57BL6 (n = 7; A) and Balb/c mice (n = 8; B) were injected
with 3 mg of MSU crystals or PBS and peritoneal lavage was performed 2 h later. C3a and C5a levels in the peritoneal lavage were measured by ELISA. Values are
shown as means ± standard error. ∗∗∗p < 0.001.
C3−/− mice was significantly suppressed (Figures 3A,B),
indicating that complement proteins play an important role in
regulating neutrophil and monocyte recruitment in mice, thereby
promoting gouty inflammation.
C5a is the Major Contributor to
Leukocyte Infiltration during
MSU-Induced Peritonitis
Active C3a and C5a are potent inflammatory mediators and
chemoattractants for phagocytic cells, including neutrophils
and monocytes. Early case reports found increased levels
of C3a/C3adesArg in two patients with gout (Moxley and
Ruddy, 1985; Jose et al., 1990); we therefore investigated
whether C3a and C5a generated by MSU crystals in vivo
are responsible for leukocyte infiltration. First, we induced
MSU-elicited peritonitis in mice deficient in both C3a and
C5a receptors (C3ar1−/−C5ar1−/−): significantly fewer
neutrophils and monocytes were present in peritoneal lavage
fluid from C3ar1−/−C5ar1−/− mice compared with WT
controls (Figure 4A), indicating that anaphylatoxin-mediated
signaling regulates leukocyte infiltration following MSU
administration in vivo.
To refine our understanding of the roles played by C3a and
C5a in MSU-elicited peritoneal neutrophil recruitment in vivo,
mice deficient in C3aR alone, C5aR alone, and WT controls were
injected i.p. with MSU crystals. Significantly fewer neutrophils
were present in the peritoneal lavage fluid of C5ar1−/− mice
(Figure 4C), but not C3ar1−/− mice (Figure 4B), compared to
WT controls, indicating that C5aR, but not C3aR, signaling is
crucial for neutrophil infiltration. We also observed a tendency
toward a reduction of monocyte recruitment in C5ar−/− mice
compered to WT controls, but this difference does not reach
statistical significance.
Human C5a receptor cyclic/linear antagonistic peptides have
been used to suppress inflammation in experimental rodent
models of inflammatory bowel disease, ischemia/reperfusion
injury, and immune complex glomerulonephritis (Paczkowski
et al., 1999; Short et al., 1999; March et al., 2004; Alexander
et al., 2015). Therefore, we sought to determine whether a
C5aR antagonist could also suppress C5a-mediated recruitment
of neutrophils and monocytes in mice after MSU challenge.
WT mice were treated i.p. with the C5aR antagonist or vehicle
prior to MSU challenge; peritoneal lavage after 6 h revealed
that mice pretreated with the C5aR antagonist peptide had
significantly fewer neutrophils and monocytes in their peritoneal
cavity compared to mice receiving vehicle alone (Figure 4D). Our
results support a central role for C5a-mediated signaling in the
MSU-elicited pathology caused largely by neutrophil infiltration
in mice.
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FIGURE 3 | C3 regulates recruitment of neutrophils and monocytes in vivo upon MSU challenge. MSU crystals (3 mg) were injected i.p. into WT or C3−/−
mice. After 6 h, peritoneal cells were collected by lavage, and the numbers of neutrophils (CD11b+Ly6G+) and monocytes (CD11b+Ly6C+Ly6G−) counted by flow
cytometry. Representative dot plots are shown in (A), the mean total number of cells for each condition is shown in (B) as means ± standard error (n = 7 per
condition). ∗∗∗p < 0.001; ∗∗p < 0.01.
C5a Regulates IL-1β Production In vivo
Induced by MSU Crystals
The importance of neutrophils and proinflammatory cytokines
in MSU-induced inflammation led us to analyze, in more detail,
the mechanisms underlying neutrophil recruitment induced by
C5a. Recently, basic and clinical research studies have implicated
IL-1β and its maturation by the NLRP3 inflammasome in the
pathogenesis of gout (Martinon et al., 2006; So et al., 2007; Kono
et al., 2010). IL-1β released from macrophages activates IL-1
receptors on epithelial cells and resident macrophages, leading
to the release of pro-inflammatory cytokines and chemokines,
which, in turn, recruit and activate leukocytes, amplifying the
inflammatory positive-feedback loop (Kono et al., 2010). This
inflammatory cascade is the major cause of gout. IL-1 receptor
antagonists, such as IL-1RA or Anakinra, or anti-human IL-
1β antibodies, suppress the acute neutrophil response to MSU
challenge in mice (So et al., 2007; Schlesinger, 2012; Ottaviani
et al., 2013; Goh et al., 2014), providing robust evidence
that this pathway is major target for beneficial therapeutic
interventions.
Because we previously demonstrated that C5a is crucial for
leukocyte recruitment upon MSU challenge in vivo, we next
sought to determine whether C5a regulates IL-1β production. IL-
1β levels were measured in the peritoneal lavage fluid collected
from WT and C3−/− mice: IL-1β levels were significantly lower
in C3−/− mice compared with WT mice (Figure 5A). To assess
the contribution of C3a and C5a signaling in IL-1β production
induced by MSU crystals in vivo, IL-1β levels were also measured
in peritoneal lavage of C3ar1−/− (C3aR−/−) or C5ar1−/−
(C5aR−/−) mice: MSU administration induced abundant and
comparable IL-1β production in WT and C3ar1−/− mice, but
far less so in C5ar1−/− mice (Figure 5B). These results indicate
that C5a generated by complement activation induced by MSU
triggers IL-1β production in vivo, which in turn regulates
neutrophil recruitment.
C5a Triggers ROS Production in
Macrophages
To gain insight into the molecular mechanisms by which C5a
induces IL-1β in peritoneal macrophages, we first examined
the possibility that C5aR signaling primes and/or activates
the NLRP3 inflammasome. Peritoneal macrophages were
exposed to LPS alone (a classical NLRP3 priming signal),
C5a alone, or LPS in combination with C5a, for 4 h before
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FIGURE 4 | C5a, but not C3a, regulates recruitment of neutrophils in vivo upon MSU challenge. Neutrophil and monocyte recruitment was measured in the
peritoneal cavity of WT (n = 6), C3ar1−/−C5ar1−/− (n = 4; A), C3ar1−/− (n = 4; B) and C5ar1−/− (n = 6; C) mice 6 h after MSU crystal injection. (D) Mice (n = 6)
received an i.p. injection of a linear C5aR antagonistic peptide prior to receiving MSU crystals. Leukocyte influx was then assessed after 6 h by flow cytometry.
∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05. nd, none detected.
FIGURE 5 | IL-1β production is impaired in C3−/− and C5ar−/− mice after MSU challenge in vivo. IL-1β levels were measured in peritoneal lavage fluids
from WT (n = 6), C3−/− (n = 6; A), C3ar1−/− (C3aR−/−; n = 5), and C5ar1−/− (C5aR−/−; n = 13) mice (B) 2 h after i.p. injection of MSU crystals. Values are
shown as means ± standard error. ∗∗p < 0.01; ∗p < 0.05.
quantification of the abundance of mRNA transcripts of
the inflammasome components Nlrp3, Asc and Casp1,
as well as Il1b and Il1a. While LPS robustly triggered
Nlrp3, Il1b and Il1a transcription, C5a alone failed to do so
(Figure 6A), and can therefore not be considered a priming
stimulus.
Next we sought to investigate alternate mechanisms by
which C5a boosts NLRP3 inflammasome activation. Since
ROS have been shown to act as a primary inducer of
NLRP3 inflammasome activity, we asked whether C5a,
alike to MSU, triggers ROS production. We found that C5a
exposure robustly increased ROS production in peritoneal
macrophages (Figure 6B), suggesting that C5a is likely
to increase NLRP3 activation at least in part via ROS
production.
DISCUSSION
The anaphylatoxin C5a is generated upon complement activation
and contributes to the development of many inflammatory
disorders, including glomerulonephritis (Welch, 2002),
pulmonary hypersensitivity (Shushakova et al., 2002), and
contact hypersensitivity (Tsuji et al., 2000). C5a is a potent
mediator of the inflammatory response as a result of its ability,
upon engagement of C5a receptors, to regulate vasodilation and
to mediate chemotaxis and activation of inflammatory leukocytes
(granulocytes, mast cells, and macrophages; Merle et al., 2015b).
However, whether C5a is crucial in vivo for gouty inflammation
was unclear. In the present study, we identify C5a generated by
MSU crystals in vivo as one of the key regulators of IL-1β release,
which in turn triggers the recruitment of neutrophils, a hallmark
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FIGURE 6 | C5a robustly elicits ROS production in peritoneal macrophages. (A) Expression of Nlrp3, Asc, Casp1, Il1b and Il1a genes was measured in
macrophages stimulated with LPS alone (0.1 µg/ml), C5a alone (50 ng/ml) or LPS in combination with C5a, by real-time quantitative RT-PCR. Results were
calculated using the 11Ct method and data presented as mean +/− standard deviations of three biological replicates. (B) ROS production evaluated as H2DCF-DA
incorporation into macrophages stimulated with C5a (50 ng/ml) or medium. ROS levels are represented as the percentage increase in treated samples relative to
untreated samples (UT) and the error is represented as the standard deviation. AU, arbitrary units.
FIGURE 7 | Model of C5a-induced IL-1β release and leukocyte infiltration upon MSU crystal challenge in vivo. Peritoneal administration of MSU crystals
causes activation of the complement system, which leads to the generation of the anaphylatoxin C5a. Upon engagement of its own receptor, C5a in turn elicits the
activation of the NLRP3 inflammasome, leading to IL-1β release. This triggers the release of chemokines from resident cells, which recruit inflammatory cells (i.e.,
neutrophils, monocytes) to the tissue site. Activated inflammatory leukocytes, cytokines, and chemokines contribute to the chronic inflammation that can lead to
bone erosion and cartilage loss. Therapeutic blockade of C5aR signaling in humans may be an alternative new approach to ameliorate the inflammatory attack in
gouty arthritis.
of gouty inflammation (Figure 7). Specifically, C5aR deficiency
was associated with less neutrophil infiltration induced by MSU
crystals in vivo, and lower IL-1β levels.
Early studies suggested that MSU crystals can promote
inflammation through complement activation: complement
proteins can deposit on the MSU crystal surface leading to the
activation of the classical and alternative complement pathways
(Russell et al., 1982; Doherty et al., 1983). Rabbits deficient in
the complement component C6, critical for MAC formation,
have diminished joint swelling in a model of experimental gout
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arthritis, associated with decreased recruitment of inflammatory
leukocytes, particularly neutrophils, and lower IL-8 levels in the
joint (Tramontini et al., 2004). Our data demonstrate that C5a-
mediated signaling is also crucial for the ingress of neutrophils
into the peritoneal cavity in response to MSU crystals in vivo.
Since C5ar−/− mice are able to assemble MAC, our results
indicate that C5a is likely to play a role that supersedes that of
the MAC in sterile crystal-induced inflammation in mice.
What are the mechanisms triggering C5a-mediated IL-1
release in response to MSU crystals in vivo? Recent data from our
and other groups have shown the critical role of the complement
system in promoting NLRP3 inflammasome activation leading
to IL-1β release (Laudisi et al., 2013; Triantafilou et al., 2013;
An et al., 2014; Cumpelik et al., 2015). It was reported that
C5a stimulation induced pro-IL-1β expression and IL-1β release
in human primary monocytes in a dose-dependent manner
following a mechanism that requires Ca2+ and K+ fluxes, and
cathepsin B activity (An et al., 2014). C5aR blocking using
an anti-C5aR antibody abolished the expression of pro-IL-1β
and caspase-1 activation in vitro (An et al., 2014). We found
that in vitro C5a exposure of mouse peritoneal macrophages
did not trigger increased transcription of the inflammasome
proteins Nlrp3, Asc and Casp1, or of Il1β and Il1α, but instead
boosted ROS production. These findings highlight the fact that
although the mechanism may diverge in different cell types
(An et al., 2014; Cumpelik et al., 2015), C5a/C5aR interactions
do provoke inflammasome activation and thereby IL-1 release.
Beside IL-1, other mechanisms elicited by MSU-induced C5a
in vivo may exist. C5a shows chemoattractant properties for
neutrophils and monocytes in other model of inflammation.
Thus, on one side, MSU-elicited C5a can induce production of
IL-1 and on the other side, lead to chemotaxis of inflammatory
leukocytes.
We have shown that MSU crystals also elicit the generation
of the anaphylatoxin, C3a. The possible contribution of C3a
to the mobilization of leukocytes during sterile inflammation
has not been reported: we found that C3a does not synergize
with the priming signal LPS in boosting pro-inflammatory
cytokine production, such as IL-1α and IL-1β, from mouse
peritoneal macrophages stimulated in vitro with LPS/MSU
crystals, and that C3aR deficiency did not diminish leukocyte
influx or IL-1β levels induced by MSU crystals in vivo.
These data indicate that C3aR signaling is dispensable for
acute MSU crystal-induced inflammation and highlight the
distinct roles of C3a and C5a. Although C3a and C5a receptor
signaling pathways share a high degree of functional overlap
(e.g., cAMP, MAPK/ERK, NF-κB pathways), our data indicate
that C3a is not directly involved in NLRP3 inflammasome
activation and induction of IL-1β release in MSU-induced
inflammation both in vitro and in vivo. It would be of
particular interest in future studies to identify C5a-specific
mechanisms that regulate inflammasome activation in the
context of sterile inflammation, as well as to define the pro- and
anti-inflammatory effector functions elicited by C5a. A recent
study has shown that neutrophil-derived microvesicles isolated
from human synovial fluid within 1 day of an acute gout
attack exhibit anti-inflammatory effects through inhibition of
C5a signaling and NLRP3 inflammasome activation (Cumpelik
et al., 2015).
Studies assessing the efficacy of antibodies or antagonistic
peptides blocking C5a function in gouty arthritis are lacking.
However, C5 blockers are currently in use in clinical and pre-
clinical studies for a number of other diseases. Eculizumab
(Soliris R©), a humanized anti-C5 monoclonal antibody, prevents
C5 from being cleaved into C5a and C5b by C5 convertase, and
is currently in trials for paroxysmal nocturnal hemoglobinuria
(PNH) and atypical hemolytic uremic syndrome (aHUS), with
plans to extend its use to age-related macular degeneration,
myasthenia gravis, optic neuritis, early septic organ dysfunction,
and prevention of rejection of kidney transplants (Melis et al.,
2015; Risitano, 2015; Horiuchi and Tsukamoto, 2016). In addition
to C5 antibodies, peptidic and non-peptidic C5aR antagonists
are in clinical trials, and some have been proven efficacious
(Morgan and Harris, 2015). Anti-complement agents have
received attention as a new treatment strategy for refractory
inflammatory diseases: considering the close link between
complement and rheumatic diseases it would also be important
to test anti-complement agents in these diseases. Our findings
suggest the possibility that C5 inhibitors may be an alternative
approach to diminish IL-1-mediated neutrophil infiltration
associated with crystal-induced acute inflammation, with the
potential to lead to amelioration of acute and chronic gouty
arthritis.
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